NovoCure (NVCR) Receivables - Net (2014 - 2026)

NovoCure's Receivables - Net history runs 13 years deep, the most recent figure standing at $53.1 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 56.07% year-over-year to $53.1 million; the TTM figure through Mar 2026 stood at $53.1 million (up 56.07% YoY), while the FY2025 annual figure was $58.7 million, up 67.32% from the prior year.
• Receivables - Net came in at $53.1 million for Q1 2026 at NovoCure, down from $58.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $101.0 million in Q1 2022 to a low of $17.5 million in Q3 2022.
• A 5-year average of $55.6 million and a median of $58.7 million in 2025 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 443.65% in 2022 and plunged 53.71% in 2024, its largest moves.
• NovoCure's Receivables - Net stood at $26.0 million in 2022, then declined by 12.64% to $22.7 million in 2023, then jumped by 54.62% to $35.1 million in 2024, then surged by 67.32% to $58.7 million in 2025, then declined by 9.44% to $53.1 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $53.1 million, $58.7 million, and $85.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison